For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase ( ...

Tenaya plans to present data from its pediatric non-interventional natural history study, known as MyClimb, in the second ...

Tenaya Therapeutics (TNYA) provided an update on its clinical development programs and outlined its strategic priorities for 2025. Updates: ...

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target of ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

A study led by Aston University's Dr Gemma Heath and Dr Prasad Nagakumar from Birmingham Children's Hospital, has shown that treatment and diagnosis for preschool wheeze needs more effective ...

Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...

PDUFA Target Action Date for Aficamten Set for September 26, 2025;Commercial Launch Preparations Underway for First Potential Approval Five-Year Aspirations Outline Corporate Strategies to Becoming Le ...

India News Live: Stay informed with our live blog covering India’s latest in politics, economy, crime, and general news. Get real-time updates on political developments, financial trends, crime ...